Nuclear roundness variance predicts prostate cancer progression, metastasis, and death: A prospective evaluation with up to 25 years of follow‐up after radical prostatectomy

Nuclear structure is often altered in cancer due to spatial rearrangements of chromatin organization via activation of oncogenes and other chromatin remodeling genes. Therefore, we evaluated the prognostic value of nuclear roundness variance (NRV) for prostate cancer (PCa) progression, metastasis and PCa‐specific death free survivals in a cohort of 116 men after radical prostatectomy (RP).

[1]  Robert W Veltri,et al.  Using nuclear morphometry to predict the need for treatment among men with low grade, low stage prostate cancer enrolled in a program of expectant management with curative intent , 2008, The Prostate.

[2]  A. Partin,et al.  Deoxyribonucleic acid ploidy analysis as a predictor of recurrence following radical prostatectomy for stage T2 disease. , 1995, The Journal of urology.

[3]  E N Atkinson,et al.  Quantitative nuclear morphometry by image analysis for prediction of recurrence of ductal carcinoma in situ of the breast. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[4]  R W Veltri,et al.  Quantitative nuclear morphometry, Markovian texture descriptors, and DNA content captured on a CAS-200 Image analysis system, combined with PCNA and HER-2/neu immunohistochemistry for prediction of prostate cancer progression. , 1994, Journal of cellular biochemistry. Supplement.

[5]  D. Gleason,et al.  Histologic grading of prostate cancer: a perspective. , 1992, Human pathology.

[6]  G. Auer,et al.  Analysis of nuclear DNA and morphometry, and proliferating cell nuclear antigen in primary and metastatic malignant melanoma. , 1997, Scandinavian journal of plastic and reconstructive surgery and hand surgery.

[7]  A W Partin,et al.  Nuclear roundness factor measurement for assessment of prognosis of patients with prostatic carcinoma. I. Testing of a digitization system. , 1988, The Journal of urology.

[8]  E. Metter,et al.  Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. , 2007, The Journal of urology.

[9]  J. Epstein,et al.  Nuclear roundness factor. A predictor of progression in untreated stage A2 prostate cancer , 1984, Cancer.

[10]  A W Partin,et al.  Natural history of progression after PSA elevation following radical prostatectomy. , 1999, JAMA.

[11]  D. S. Coffey,et al.  Computerized image analysis of nuclear shape as a prognostic factor for prostatic cancer , 1982, The Prostate.

[12]  A. Eynard,et al.  Assessment of colorectal cancer prognosis through nuclear morphometry. , 2009, The Journal of surgical research.

[13]  Jonathan A. Cooper,et al.  Role of epidermal growth factor‐stimulated protein kinase in control of proliferation of A431 cells , 1982, Journal of cellular biochemistry.

[14]  E. Platz,et al.  Epidemiology of inflammation and prostate cancer. , 2004, The Journal of urology.

[15]  P. V. van Diest,et al.  Valproic acid causes dose- and time-dependent changes in nuclear structure in prostate cancer cells in vitro and in vivo , 2008, Molecular Cancer Therapeutics.

[16]  M. Tsuneyoshi,et al.  Nuclear morphometry and the MIB-1 index in rhabdomyosarcoma , 1996 .

[17]  G S Stein,et al.  Nuclear structure-gene expression interrelationships: implications for aberrant gene expression in cancer. , 2000, Cancer research.

[18]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[19]  T. DeWeese,et al.  The Diet, Prostate Inflammation, and the Development of Prostate Cancer , 2004, Cancer and Metastasis Reviews.

[20]  A. Partin,et al.  The use of nuclear morphometry to predict response to therapy in Wilms' tumor , 1992, Cancer.

[21]  T. Guthrie,et al.  Prostate cancer. , 2020, American family physician.

[22]  T. Högberg,et al.  Nuclear morphometry: a strong prognostic factor for survival after secondary surgery in advanced ovarian cancer , 1991, International Journal of Gynecologic Cancer.

[23]  A W Partin,et al.  Nuclear morphometry adds significant prognostic information to stage and grade for renal cell carcinoma. , 1999, Urology.

[24]  A. Partin,et al.  The use of nuclear morphometry in predicting recurrence of transitional cell carcinoma. , 1993, The Journal of urology.

[25]  D. Tindall,et al.  p300 in prostate cancer proliferation and progression. , 2003, Cancer research.

[26]  A W Partin,et al.  A comparison of nuclear morphometry and Gleason grade as a predictor of prognosis in stage A2 prostate cancer: a critical analysis. , 1989, The Journal of urology.

[27]  V. Kosma,et al.  NUCLEAR MORPHOMETRY AS A PREDICTOR OF DISEASE OUTCOME IN GASTRIC CANCER , 1997, The Journal of pathology.

[28]  D. Tindall,et al.  p300 modulates nuclear morphology in prostate cancer. , 2005, Cancer research.

[29]  P. Tan,et al.  Correlation of Nuclear Morphometry with Pathologic Parameters in Ductal Carcinoma In Situ of the Breast , 2001, Modern Pathology.

[30]  A. Partin,et al.  Significant variations in nuclear structure occur between and within Gleason grading patterns 3, 4, and 5 determined by digital image analysis , 2007, The Prostate.

[31]  A W Partin,et al.  Nuclear roundness factor measurement for assessment of prognosis of patients with prostatic carcinoma. II. Standardization of methodology for histologic sections. , 1988, The Journal of urology.

[32]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[33]  L. Tanoue.  Cancer Statistics, 2009 , 2010 .

[34]  A. Partin,et al.  Use of nuclear morphometry, gleason histologic scoring, clinical stage, and age to predict disease‐free survival among patients with prostate cancer , 1992, Cancer.

[35]  A. Partin,et al.  Long‐Term assessment of prostate cancer progression free survival: Evaluation of pathological parameters, nuclear shape and molecular biomarkers of pathogenesis , 2008, The Prostate.

[36]  Robert W Veltri,et al.  Prediction of Prostate-Specific Antigen Recurrence in Men with Long-term Follow-up Postprostatectomy Using Quantitative Nuclear Morphometry , 2008, Cancer Epidemiology Biomarkers & Prevention.

[37]  A. Partin,et al.  p300 (histone acetyltransferase) biomarker predicts prostate cancer biochemical recurrence and correlates with changes in epithelia nuclear size and shape , 2008, The Prostate.

[38]  Osamu Yoshida,et al.  Nuclear morphometry for improved prediction of the prognosis of human bladder carcinoma , 1995, Cancer.

[39]  W. Isaacs,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group. Pathological and Molecular Aspects of Prostate Cancer Prostate Cancer Ii , 2022 .

[40]  Shihua He,et al.  Chromatin organization and nuclear microenvironments in cancer cells , 2008, Journal of cellular biochemistry.